Papers/PMID:16280069
The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis.
Critical care (London, England)2005The record
3 findings · 1 compound · 3 endpoints · 3 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
3 findings
fluconazole — no detected effect on all-cause mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The use of prophylactic fluconazole was associated with a reduction in the proportion of patients with candidaemia (RR = 0.21, 95% CI = 0.06–0.72, P = 0.01; I2 = 0%) and fungal infections other than lower urinary tract infection (RR = 0.39, 95% CI = 0.24–0.65, P = 0.0003; I2 = 0%), but was associated with no significant difference in hospital mortality (RR = 0.82, 95% CI = 0.62–1.08, P = 0.15; I2 = 7%).”
Quoted verbatim from The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis.. - Study
- meta-analysis
- Dose
- 100 to 800 mg/day
- Population
- Immunocompetent high-risk surgical adult patients in seven randomised trials of prophylactic fluconazole versus placebo; pooled routes (five intravenous, one enteral, one either)
Effect 0.82 risk ratio, 95% CI 0.62 to 1.08
The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis.2005PMID:16280069Industry fundedPermalink
fluconazole — no detected effect on hospital length of stay
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The total length of hospital stay was no different between the fluconazole group and the placebo group (weight mean difference = -0.4 days, 95% CI = -10.35 to 9.54, P = 0.94; I2 = 52.4%).”
Quoted verbatim from The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis.. - Study
- meta-analysis
- Dose
- 100 to 800 mg/day
- Population
- Immunocompetent high-risk surgical adult patients in randomised trials of prophylactic fluconazole versus placebo; pooled routes (five intravenous, one enteral, one either)
Effect -0.4 mean difference, 95% CI -10.35 to 9.54
The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis.2005PMID:16280069Industry fundedPermalink
fluconazole — no detected effect on withdrawal due to adverse events
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The proportion of patients colonised with or infected with fluconazole-resistant fungi (RR = 0.66, 95% CI = 0.22–1.96, P = 0.46; I2 = 0%) and the proportion of patients with adverse events leading to cessation of the study drug (RR = 0.75, 95% CI = 0.22–2.58, P = 0.65; I2 = 0%) were not different between the fluconazole group and the placebo group.”
Quoted verbatim from The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis.. - Study
- meta-analysis
- Dose
- 100 to 800 mg/day
- Population
- Immunocompetent high-risk surgical adult patients in randomised trials of prophylactic fluconazole versus placebo; pooled routes (five intravenous, one enteral, one either)
Effect 0.75 risk ratio, 95% CI 0.22 to 2.58
The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis.2005PMID:16280069Industry fundedPermalink